TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 852890

Group type: EXPERIMENTAL
Intervention: 350 mg pivampicillin tablets
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: 350 mg pivampicillin tablets (fasting)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: 350 mg pivampicillin tablets (non-fasting)
Number of subjects: 470
Study: 30727810

Group type: EXPERIMENTAL
Intervention: Behavioral medicine approach to physical therapy (BMPI)
Number of subjects: 12
Study: 31424182

Group type: EXPERIMENTAL
Intervention: 2 mA anodal tDCS over the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 10
Study: 28849588

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg twice daily
Number of subjects: 80
Study: 25986004

Group type: EXPERIMENTAL
Intervention: Feedback intervention (feedback of analysed audit data)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control wards
Number of subjects: 0
Study: 24195291

Group type: EXPERIMENTAL
Intervention: CpG oligodeoxynucleotide (ODN) stimulation
Number of subjects: 0
Study: 21602648

Group type: EXPERIMENTAL
Intervention: Strength Training Group (TG)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 49
Study: 19843481

Group type: EXPERIMENTAL
Intervention: bepotastine besilate ophthalmic solution 1.0%
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: bepotastine besilate ophthalmic solution 1.5%
Number of subjects: 107

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: bepotastine besilate ophthalmic solution 1.0% and 1.5%
Number of subjects: 107
Study: 16944409

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1203

Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 1203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1203

Group type: EXPERIMENTAL
Intervention: Escitalopram vs Citalopram
Number of subjects: 1203

Group type: EXPERIMENTAL
Intervention: CGI-S and CGI-I
Number of subjects: 1203
Study: 15517747

Group type: EXPERIMENTAL
Intervention: Hydropolymer foam dressing (Tielle, Johnson & Johnson)
Number of subjects: 140
Study: 11073179

Group type: EXPERIMENTAL
Intervention: Integrated diabetic footcare model
Number of subjects: 1939
Study: 9293128

Group type: EXPERIMENTAL
Intervention: IOTN learning package used by test group GDPs
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no IOTN learning package)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Test group GDPs
Number of subjects: 40
Study: 8448066

Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3298412

Group type: EXPERIMENTAL
Intervention: human lymphoblastoid interferon (Wellferon) given for 28 consecutive days at a dosage ranging from 2.5 to 7.5 MU/m2 i.m.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (10 patients)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: human lymphoblastoid interferon (Wellferon)
Number of subjects: 8
Study: 30237705

Group type: EXPERIMENTAL
Intervention: Aerobic dance routine + usual care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 60
Study: 26912478

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Number of subjects: 13
Study: 23860273

Group type: EXPERIMENTAL
Intervention: TY-51924 (up to 30 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22439653

Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation counselling (face-to-face visits weekly for the first four weeks, monthly to six months, and two monthly to 12 months) and encouragement to attend a monthly smoking cessation support group.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 20197741

Group type: EXPERIMENTAL
Intervention: Kouriles Acne
Number of subjects: 29
Study: 18678295

Group type: EXPERIMENTAL
Intervention: High-dose clopidogrel (600 mg loading immediately before PCI and 75 mg 2 times/day for 1 month)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard-dose clopidogrel (300 mg loading and 75 mg/day)
Number of subjects: 119
Study: 15620444

Group type: EXPERIMENTAL
Intervention: Gentamicin-collagen implant
Number of subjects: 542

Group type: COMPARATOR
Intervention: Control (routine intravenous antimicrobial prophylaxis)
Number of subjects: 542
Study: 12560779

Group type: EXPERIMENTAL
Intervention: Portal vein embolization (PVE) before right hepatectomy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Immediate surgery without PVE
Number of subjects: 55
Study: 10379218

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (trimethoprim TMP‐SMZ, nitrofurantoin, or a quinolone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent patient‐administered treatment (taken at the onset of symptoms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long‐term prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine investigation of the urinary tract (excretory urography, ultrasonography, cystoscopy, voiding cystourethrography)
Number of subjects: 0
Study: 8929005

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy
Number of subjects: 2589

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 2589
Study: 2058162

Group type: COMPARATOR
Intervention: Omega-3 fatty acids (8 capsules Ameu per day) for 21 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omega-3 fatty acids (8 capsules Ameu per day) for 56 days
Number of subjects: 0
Study: 6858170

Group type: EXPERIMENTAL
Intervention: Jopamidol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Meglumine iodamine
Number of subjects: 80
Study: 30387697

Group type: EXPERIMENTAL
Intervention: Platelet transfusion at a threshold of 50,000 per cubic millimeter (high-threshold group)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Platelet transfusion at a threshold of 25,000 per cubic millimeter (low-threshold group)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: High-threshold group
Number of subjects: 660

Group type: COMPARATOR
Intervention: Low-threshold group
Number of subjects: 660
Study: 29914484

Group type: EXPERIMENTAL
Intervention: Role-playing simulation (experimental group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lecture on TPE (comparison group)
Number of subjects: 0
Study: 26565005

Group type: EXPERIMENTAL
Intervention: 80 mg lovastatin for 5 days
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 24571189

Group type: EXPERIMENTAL
Intervention: Health Coaching (HC)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 186
Study: 20665751

Group type: EXPERIMENTAL
Intervention: SSc patients
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Diffuse cutaneous SSc subgroup
Number of subjects: 25
Study: 19861267

Group type: EXPERIMENTAL
Intervention: PFVA and TEAS at Hegu‐Laogong and Neiguan‐WaiGuan acupoints (Group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: PFVA and TEAS at Hegu‐Laogong, Neiguan‐Waiguan, and bilateral Jianjing acupoints (Group C)
Number of subjects: 90

Group type: COMPARATOR
Intervention: PFVA (Group A)
Number of subjects: 90
Study: 17718820

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB) at doses of 12.5 microg, 20 microg, 25 microg, and 50 microg.
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB)
Number of subjects: 17
Study: 15733401

Group type: EXPERIMENTAL
Intervention: Standard heparin (n = 37)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (n = 31)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (n = 39)
Number of subjects: 107
Study: 11680354

Group type: EXPERIMENTAL
Intervention: Prilocaine plain
Number of subjects: 310

Group type: COMPARATOR
Intervention: Lidocaine with 1:100,000 epinephrine
Number of subjects: 310
Study: 9709279

Group type: EXPERIMENTAL
Intervention: Breast cancer screening offered
Number of subjects: 0

Group type: COMPARATOR
Intervention: No breast cancer screening offered (control)
Number of subjects: 0
Study: 7886187

Group type: EXPERIMENTAL
Intervention: Alcohol (0.83 ml ethanol/kg body weight)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2838344

Group type: EXPERIMENTAL
Intervention: Clofazimine (0.01‐5 micrograms/ml)
Number of subjects: 0
Study: 30262887

Group type: EXPERIMENTAL
Intervention: Oxytocin (48 IU/day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Oxytocin (200 ng/100 μL/mouse, for 14 consecutive days)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Acute Oxytocin (200 ng/100 μL/mouse, once)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 29907608

Group type: EXPERIMENTAL
Intervention: nVNS (gammaCore)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 248
Study: 27145524

Group type: EXPERIMENTAL
Intervention: Thin-neck pacifier (TNP)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional or physiological pacifier (Control)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Gold standard, weaned off pacifier
Number of subjects: 86
Study: 24574227

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22736271

Group type: EXPERIMENTAL
Intervention: CARE: Creating Avenues for Relative Empowerment, a two-session empowerment-educational program 1-2 days post-admission and 1-3 days pre-discharge
Number of subjects: 407

Group type: COMPARATOR
Intervention: Attention control group, received a generic information program during the same timeframe
Number of subjects: 407
Study: 20407113

Group type: EXPERIMENTAL
Intervention: Hydrophilic-coated sheaths
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Uncoated sheaths
Number of subjects: 35

Group type: COMPARATOR
Intervention: Noncatheterized arm
Number of subjects: 35
Study: 18854748

Group type: EXPERIMENTAL
Intervention: Amlodipine-based treatment
Number of subjects: 5137

Group type: COMPARATOR
Intervention: Atenolol-based treatment
Number of subjects: 5137
Study: 16097419

Group type: EXPERIMENTAL
Intervention: ONCAB
Number of subjects: 20

Group type: COMPARATOR
Intervention: OFFCAB
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 11837547

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 0
Study: 10512261

Group type: COMPARATOR
Intervention: Midazolam 1 mg IV and meperidine 50 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ro 48-6791 0.5 mg IV and meperidine 50 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ro 48-6791 1.0 mg IV alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ro 48-6791 (both doses)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study: 7717282

Group type: EXPERIMENTAL
Intervention: Ibopamine (100 mg 3 times daily)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Digoxin (0.25 mg once daily)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 2251022

Group type: EXPERIMENTAL
Intervention: Tetracaine-adrenaline-cocaine (TAC)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Adrenaline-cocaine
Number of subjects: 55
Study: 6988170

Group type: EXPERIMENTAL
Intervention: Cefuroxime (1.5 g by intravenous injection prior to induction of anaesthesia)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (no antibiotics)
Number of subjects: 47
Study: 31750691

Group type: EXPERIMENTAL
Intervention: OurRelationship program (online self-help relationship intervention)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: OurRelationship program
Number of subjects: 600

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 600
Study: 31514453

Group type: COMPARATOR
Intervention: Frankel's stabilization exercises (C)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Stabilometric platform (E)
Number of subjects: 40
Study: 28554517

Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum injection
Number of subjects: 832
Study: 25826376

Group type: EXPERIMENTAL
Intervention: Stimulation and learning opportunities
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Height for age
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Weight for height z-scores
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Number of days with diarrhea
Number of subjects: 422
Study: 23819903

Group type: EXPERIMENTAL
Intervention: Comprehensive support (6 educational sessions focused on behavior change strategies and motivation with nutrition counseling)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 144
Study: 22040192

Group type: EXPERIMENTAL
Intervention: Sertraline (25-150 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 20127533

Group type: EXPERIMENTAL
Intervention: 40 mL of 0.25% levobupivacaine (LB group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (NS group)
Number of subjects: 40
Study: 16570766

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet and exercise only
Number of subjects: 0
Study: 12429673

Group type: EXPERIMENTAL
Intervention: Educational training package for primary health care teams in accident prevention
Number of subjects: 1666

Group type: COMPARATOR
Intervention: Normal practice (control group)
Number of subjects: 1666
Study: 10473477

Group type: EXPERIMENTAL
Intervention: Drug counselling
Number of subjects: 250

Group type: COMPARATOR
Intervention: Treatment leaflets
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Counselling for patients with major depressive disorder receiving doses >=75 mg
Number of subjects: 250

Group type: COMPARATOR
Intervention: No counselling for patients with major depressive disorder receiving doses >=75 mg
Number of subjects: 250
Study: 8758157

Group type: EXPERIMENTAL
Intervention: Bupivacaine-induced spinal block
Number of subjects: 105

Group type: COMPARATOR
Intervention: Intramuscular bupivacaine 12.5 mg
Number of subjects: 105
Study: 1956009

Group type: EXPERIMENTAL
Intervention: Hulka clip application
Number of subjects: 50

Group type: COMPARATOR
Intervention: Modified Pomeroy tubal ligation
Number of subjects: 50
Study: 6918920

Group type: EXPERIMENTAL
Intervention: Oxygen inhalation at 2 liters per minute for 30 minutes
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oxygen inhalation at 4 liters per minute for 30 minutes
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oxygen inhalation at 6 liters per minute for 30 minutes
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no oxygen inhalation)
Number of subjects: 100
Study: 31876454

Group type: EXPERIMENTAL
Intervention: Exercise in heat (37.41°C)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standing in heat (37.56°C)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Exercise in ambient temperature (14.24°C)
Number of subjects: 13
Study: 30782008

Group type: EXPERIMENTAL
Intervention: DVD intervention (the Sleep Easy Solution)
Number of subjects: 239
Study: 28448664

Group type: EXPERIMENTAL
Intervention: 0.25 mg intravitreous bevacizumab
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 0.125 mg intravitreous bevacizumab
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 0.063 mg intravitreous bevacizumab
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 0.031 mg intravitreous bevacizumab
Number of subjects: 61
Study: 26393847

Group type: EXPERIMENTAL
Intervention: Dextromethorphan-quinidine
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 24108114

Group type: EXPERIMENTAL
Intervention: Profermin
Number of subjects: 74

Group type: COMPARATOR
Intervention: Fresubin
Number of subjects: 74
Study: 21339632

Group type: EXPERIMENTAL
Intervention: 1 mg of human rhGH administered from day 1 to day 7
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (placebo) administered from day 1 to day 7
Number of subjects: 30
Study: 19411369

Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study: 17426626

Group type: EXPERIMENTAL
Intervention: Computer-assisted tool for brace design and adjustment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional method for brace design and adjustment
Number of subjects: 48
Study: 15956509

Group type: EXPERIMENTAL
Intervention: 6F Closer S device (Perclose)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Literature review
Number of subjects: 416
Study: 11791086

Group type: EXPERIMENTAL
Intervention: HRT group (estradiol 2 mg and norethisterone acetate 1 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (clodronate only)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: HRT group
Number of subjects: 22
Study: 10604491

Group type: EXPERIMENTAL
Intervention: 50 mg losartan once daily
Number of subjects: 69

Group type: COMPARATOR
Intervention: 25 mg HCTZ once daily
Number of subjects: 69
Study: 7781871

Group type: EXPERIMENTAL
Intervention: Combined regimen of ipriflavone and 1 alpha vitamin D
Number of subjects: 98

Group type: COMPARATOR
Intervention: Ipriflavone alone
Number of subjects: 98

Group type: COMPARATOR
Intervention: 1 alpha vitamin D alone
Number of subjects: 98

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 98
Study: 1933081

Group type: EXPERIMENTAL
Intervention: Memory notebook training
Number of subjects: 4
Study: 7039755

Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control (no glucagon)
Number of subjects: 190
Study: 30912690

Group type: EXPERIMENTAL
Intervention: Physical exercise intervention for 45 min, once a week
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Physical exercise intervention for 15 min, three times a week
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care Control Group
Number of subjects: 60
Study: 30346913

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) over the primary motor cortex
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 19
Study: 29704398

Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (IPC)
Number of subjects: 11

Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 11
Study: 26858122

Group type: EXPERIMENTAL
Intervention: Durvalumab 20 mg/kg every 4 weeks plus tremelimumab 1 mg/kg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Durvalumab 20 mg/kg every 4 weeks plus tremelimumab 3 mg/kg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Durvalumab 3 mg/kg, 10 mg/kg, 15 mg/kg, or 20 mg/kg every 4 weeks, or 10 mg/kg every 2 weeks, plus tremelimumab 1 mg/kg, 3 mg/kg, or 10 mg/kg every 4 weeks for six doses then every 12 weeks for three doses
Number of subjects: 102
Study: 24671340

Group type: EXPERIMENTAL
Intervention: nalmefene 18 mg/day
Number of subjects: 675

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 675
Study: 23206762

Group type: EXPERIMENTAL
Intervention: Minimally invasive percutaneous nephrolithotomy with the aid of a patented system
Number of subjects: 182

Group type: COMPARATOR
Intervention: Transurethral ureteroscopy
Number of subjects: 182
Study: 20703211

Group type: EXPERIMENTAL
Intervention: everolimus
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: cyclosporine (CsA)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: mycophenolate sodium (MPA)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: prednisolone (P) plus CsA
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: prednisolone (P) plus MPA
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: prednisolone (P) plus everolimus
Number of subjects: 36
Study: 18372684

Group type: EXPERIMENTAL
Intervention: Inertial mechanical loading (2.5 G at the feet decreasing to 1 G at the heart) for 60 min daily during 21 days of head-down bed rest
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (instrumented but did not receive centrifugation)
Number of subjects: 0
Study: 16404960

Group type: EXPERIMENTAL
Intervention: Modified endoscopic surgical procedure by J. Destandau
Number of subjects: 58

Group type: COMPARATOR
Intervention: Routine endoscopic surgical procedure
Number of subjects: 58
Study: 11966384

Group type: EXPERIMENTAL
Intervention: Restorative care
Number of subjects: 691
Study: 9619219

Group type: EXPERIMENTAL
Intervention: PEEP
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: IRV
Number of subjects: 24

Group type: COMPARATOR
Intervention: Manual inflations
Number of subjects: 24

Group type: COMPARATOR
Intervention: Large tidal volumes
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pressure control IRV
Number of subjects: 24
Study: 7617869

Group type: EXPERIMENTAL
Intervention: Magnetization-transfer measurements in patients with MS
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 23
Study: 2508190

Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO) 500 mg administered four hours prior to irradiation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Radiation alone (40 Gy to the pelvic region)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Misonidazole combined with radiation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 44
Study: 73353

Group type: EXPERIMENTAL
Intervention: nalbuphine (0.1 mg/kg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: morphine (0.1 mg/kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 75
Study: 31719190

Group type: EXPERIMENTAL
Intervention: MI‐E+O (Mechanical In-Exsufflation with Oscillations)
Number of subjects: 56

Group type: COMPARATOR
Intervention: MI‐E (Mechanical In-Exsufflation)
Number of subjects: 56
Study: 29665992

Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin (group A)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Intralesional triamcinolone (group B)
Number of subjects: 67